share_log

RNAZ Stock Alert: The Breast Cancer Study News Sending TransCode Therapeutics Soaring Today

RNAZ Stock Alert: The Breast Cancer Study News Sending TransCode Therapeutics Soaring Today

RNAZ股票警報:乳腺癌研究消息使轉碼治療藥物今天飆升
InvestorPlace ·  2021/09/23 12:48

TransCode Therapeutics (NASDAQ:RNAZ) stock is rocketing higher on Thursday as investors react to positive news from a breast cancer study.

代碼轉換治療學(納斯達克:RNAZ)週四,隨着投資者對一項乳腺癌研究的積極消息做出反應,股價飆升。

Source: Bukhta Yurii / Shutterstock.com

來源:Bukhta Yurii/Shutterstock.com

According to a press release from the company, preclinical trial data for TTX-MC138 shows that it could be an effective treatment of breast cancer. TTX-MC138 is an RNA therapeutics treatment in development from the company.

根據該公司的一份新聞稿,TTX-MC138的臨牀前試驗數據表明,它可能是一種有效的乳腺癌治療方法。TTX-MC138是該公司正在開發的RNA療法。

Results from the preclinical study were published in Cancer Nanotechnology. It’s under the title “Radiolabeling and PET-MRI microdosing of the experimental cancer therapeutic, MN-anti-miR10b, demonstrates delivery to metastic lesions in a murine model of metastatic breast cancer.”

臨牀前研究的結果發表在癌症納米技術。它的標題是“實驗性癌症治療藥物MN-anti-miR10b的放射標記和PET-MRI微劑量,證明瞭在轉移性乳腺癌的小鼠模型中,MN-anti-miR10b可以傳遞到轉移的病變中。”

Michael Dudley, CEO of TransCode Therapeutics, said this in the release sending RNAZ stock higher today.

轉碼治療公司首席執行官邁克爾·達德利在新聞稿中説,這推動RNAZ股價今天走高。

‘For TransCode, we believe this study further confirms the pharmacokinetic profile of TTX-MC138, supporting the viability of our platform for delivery of RNA-based therapy to metastatic solid tumors. Our preclinical data further suggest the therapeutic potential of TTX-MC138, and we look forward to our Phase 0 study which has the potential to establish clinical proof-of-concept for this therapy.”

在代碼轉換方面,我們相信這項研究進一步證實了TTX-MC138的藥代動力學特徵,支持了我們為轉移性實體腫瘤提供基於RNA的治療的平臺的可行性。我們的臨牀前數據進一步表明了TTX-MC138的治療潛力,我們期待着我們的0期研究,它有可能為這種療法建立臨牀概念驗證。“

So what does TransCode Therapeutics plan to do next? The company says it will file an exploratory investigational new drug application for TTX-MC138 in the first quarter of 2022. The goal is to use this for support of a Phase 0 study of its potential breast cancer treatment.

那麼轉碼治療公司下一步計劃做什麼呢?該公司表示,將在2022年第一季度為TTX-MC138提交探索性研究新藥申請。我們的目標是利用這一點來支持對其潛在乳腺癌治療的0期研究。

RNAZ stock is seeing heavy trading on today’s news. As of this writing, more than 147 million shares of the stock have changed hands. To put that in perspective, the company’s daily average trading volume is closer to 1.1 million shares.

受今日新聞影響,RNAZ股票交易量很大。截至撰寫本文時,該股已有超過1.47億股易手。相比之下,該公司的日均成交量接近110萬股。

RNAZ stock was up 91.4% as of Thursday afternoon.

截至週四下午,RNAZ股價上漲了91.4%。

We’ve got more of the latest stock market news investors need to know about below!

下面是投資者需要了解的更多最新股市新聞!

InvestorPlace offers deep dives into the stock market daily to assist traders. Today’s no different with us covering what thas shares of Plug Power (NASDAQ:PLUG), Novavax (NASDAQ:NVAX), and Roku (NASDAQ:ROKU) on the move. You can get all those details from the following links!

InvestorPlace提供每日深入股市的服務,以幫助交易員。今天的節目和我們分享的內容沒有什麼不同插頭電源(納斯達克:插頭), 諾華(納斯達克:NVAX),以及羅庫(納斯達克:羅庫)移動中。您可以從以下鏈接獲取所有這些詳細信息!

More Thursday Stock Market News

更多週四股市新聞

On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.

在出版之日,威廉·懷特沒有(直接或間接)持有本文所述證券的任何頭寸。本文表達的觀點是作者的觀點,以InvestorPlace.com為準出版指南.

With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risks. Read More: Penny Stocks — How to Profit Without Getting Scammed

除了最罕見的例外,InvestorPlace不會發布關於市值低於1億美元或每天交易量低於10萬股的公司的評論。這是因為這些“廉價股”經常是詐騙藝術家和市場操縱者的遊樂場。如果我們確實發佈了可能受我們的評論影響的低成交量股票的評論,我們要求 InvestorPlace.com該書的作者披露了這一事實,並警告讀者其中的風險。 更多閲讀: 便士股票-如何在不上當的情況下獲利

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論